Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:175:379-411.
doi: 10.1007/10_2020_143.

State-of-the-Art Glycomics Technologies in Glycobiotechnology

Alexander Pralow  1 , Samanta Cajic  1 , Kathirvel Alagesan  2 , Daniel Kolarich  2   3 , Erdmann Rapp  4   5
Affiliations

State-of-the-Art Glycomics Technologies in Glycobiotechnology

Alexander Pralow et al. Adv Biochem Eng Biotechnol. 2021.

Abstract

Glycosylation affects the properties of biologics; thus regulatory bodies classified it as critical quality attribute and force biopharma industry to capture and control it throughout all phases, from R&D till end of product lifetime. The shift from originators to biosimilars further increases importance and extent of glycoanalysis, which thus increases the need for technology platforms enabling reliable high-throughput and in-depth glycan analysis. In this chapter, we will first summarize on established glycoanalytical methods based on liquid chromatography focusing on hydrophilic interaction chromatography, capillary electrophoresis focusing on multiplexed capillary gel electrophoresis, and mass spectrometry focusing on matrix-assisted laser desorption; we will then highlight two emerging technologies based on porous graphitized carbon liquid chromatography and on ion-mobility mass spectrometry as both are highly promising tools to deliver an additional level of information for in-depth glycan analysis; additionally we elaborate on the advantages and challenges of different glycoanalytical technologies and their complementarity; finally, we briefly review applications thereof to biopharmaceutical products. This chapter provides an overview of current state-of-the-art analytical approaches for glycan characterization of biopharmaceuticals that can be employed to capture glycoprotein heterogeneity in a biopharmaceutical context.

Keywords: Biopharmaceuticals; Biosimilars; Capillary electrophoresis; Glycomics; Glycoprofile; Glycosylation; Liquid Chromatography; Mass spectrometry; Vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Butler M, Spearman M (2014) The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Biotechnol 30:107–112 - PubMed - DOI
    1. Fournier J (2015) A review of glycan analysis requirements. Biopharm Int 28(10):32
    1. EMA – Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products – draft (2009) 2013 updated 2013/07/21. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...
    1. Quality Guidelines: ICH (2014) 2018. updated 2018/05/17. http://www.ich.org/products/guidelines/quality/article/quality-guideline...
    1. EMA – Guideline on Influenza Vaccines – Quality module (2017) 2017. updated 2017/07/28. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...

LinkOut - more resources